ArticleJournal of molecular histology2025
Hippo signaling pathway in human testis and seminoma: anticancer effect of verteporfin on human seminoma TCam-2 cells.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimSeminoma and embryonal carcinoma are among the most common germ cell tumors. Verteporfin, a YAP-TEAD inhibitor, has emerged as a potential anticancer agent. This study investigated the localization of Hippo signaling proteins in human testis, seminoma, and non-seminoma tissues, and examined verteporfin’s effects on TCam-2 seminoma cells.
methodsProtein localization in tissues was assessed using immunohistochemistry. TCam-2 cells were treated with various concentrations of verteporfin (1–40 µM) for 24, 48, and 72 h. Protein and gene expression were analyzed via immunofluorescence, western blotting, and qRT-PCR.
resultsHippo pathway proteins showed distinct localization patterns across tissue types. Verteporfin treatment caused a dose- and time-dependent decrease in protein levels without altering mRNA expression. It also induced nuclear-to-cytoplasmic translocation of pathway proteins and reduced cell proliferation, migration, and viability, while simultaneously promoting apoptosis in TCam-2 human seminoma cells.
conclusionVerteporfin may serve as a promising therapeutic strategy for seminoma by targeting Hippo signaling. These findings support its potential role in personalized treatment approaches for testicular cancer.
Indexed as
Identifiers
40844663What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.